The impact of COVID-19 in a cohort of patients with systemic sclerosis
© 2023 Revista Médica del Instituto Mexicano del Seguro Social..
Background: COVID-19 brought with it unknowns related to systemic sclerosis.
Objective: To know the clinical evolution and prognosis of COVID-19 in a cohort of patients with systemic sclerosis.
Methods: During the pandemic, we had digital contact with a cohort of 197 patients with SSc. If they had any condition that met the suspected definition of COVID-19, they underwent polymerase chain reaction testing for SARS-CoV-2; they were treated on an outpatient or hospital basis without interfering with their treatment. They followed their evolution every 24 hours until they became asymptomatic or died.
Results: Thirteen patients (6.6%), nine diffuse cutaneous (dcSSc), and four limited cutaneous (lcSSc) developed COVID-19 during nine months of follow-up. The immunosuppressants used at the time of the disease were: mycophenolate mofetil, methotrexate, and prednisone, in low doses. Seven patients had interstitial lung disease (ILD). The main symptoms were chest pain, cough, dyspnea, dysgeusia, and anosmia, 1 with mild symptoms without pneumonia, 11 with mild pneumonia, and one with severe pneumonia that required hospital management. Only one (7.7%) presented severe pneumonia, was hospitalized, and died.
Conclusions: COVID-19 disease in patients with SSc can be overcome in most cases, even when they are ILD and were using immunosuppressants at the time of infection with the SARS-CoV-2 virus.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Revista medica del Instituto Mexicano del Seguro Social - 61(2023), 2 vom: 01. März, Seite 163-171 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
El impacto de COVID-19 en una cohorte de pacientes con esclerosis sistémica |
|---|
| Beteiligte Personen: |
Cruz-Domínguez, María Del Pilar [VerfasserIn] |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 22.05.2023 Date Revised 05.08.2023 published: Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM357037456 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357037456 | ||
| 003 | DE-627 | ||
| 005 | 20231226071729.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||spa c | ||
| 028 | 5 | 2 | |a pubmed24n1190.xml |
| 035 | |a (DE-627)NLM357037456 | ||
| 035 | |a (NLM)37201206 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Cruz-Domínguez, María Del Pilar |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The impact of COVID-19 in a cohort of patients with systemic sclerosis |
| 246 | 3 | 3 | |a El impacto de COVID-19 en una cohorte de pacientes con esclerosis sistémica |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.05.2023 | ||
| 500 | |a Date Revised 05.08.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Revista Médica del Instituto Mexicano del Seguro Social. | ||
| 520 | |a Background: COVID-19 brought with it unknowns related to systemic sclerosis | ||
| 520 | |a Objective: To know the clinical evolution and prognosis of COVID-19 in a cohort of patients with systemic sclerosis | ||
| 520 | |a Methods: During the pandemic, we had digital contact with a cohort of 197 patients with SSc. If they had any condition that met the suspected definition of COVID-19, they underwent polymerase chain reaction testing for SARS-CoV-2; they were treated on an outpatient or hospital basis without interfering with their treatment. They followed their evolution every 24 hours until they became asymptomatic or died | ||
| 520 | |a Results: Thirteen patients (6.6%), nine diffuse cutaneous (dcSSc), and four limited cutaneous (lcSSc) developed COVID-19 during nine months of follow-up. The immunosuppressants used at the time of the disease were: mycophenolate mofetil, methotrexate, and prednisone, in low doses. Seven patients had interstitial lung disease (ILD). The main symptoms were chest pain, cough, dyspnea, dysgeusia, and anosmia, 1 with mild symptoms without pneumonia, 11 with mild pneumonia, and one with severe pneumonia that required hospital management. Only one (7.7%) presented severe pneumonia, was hospitalized, and died | ||
| 520 | |a Conclusions: COVID-19 disease in patients with SSc can be overcome in most cases, even when they are ILD and were using immunosuppressants at the time of infection with the SARS-CoV-2 virus | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Coronavirus Infections | |
| 650 | 4 | |a Prognosis | |
| 650 | 4 | |a Scleroderma, Systemic | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 700 | 1 | |a Morales-Montalvo, Susana Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Vera-Lastra, Olga Lidia |e verfasserin |4 aut | |
| 700 | 1 | |a López-Zamora, Berenice |e verfasserin |4 aut | |
| 700 | 1 | |a Ordoñez-González, Irvin |e verfasserin |4 aut | |
| 700 | 1 | |a Medina-García, Gabriela |e verfasserin |4 aut | |
| 700 | 1 | |a López-Burgos, Cinthya Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Montes-Cortés, Daniel Héctor |e verfasserin |4 aut | |
| 700 | 1 | |a Jara-Quezada, Luis Javier |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista medica del Instituto Mexicano del Seguro Social |d 2005 |g 61(2023), 2 vom: 01. März, Seite 163-171 |w (DE-627)NLM156363798 |x 0443-5117 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2023 |g number:2 |g day:01 |g month:03 |g pages:163-171 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2023 |e 2 |b 01 |c 03 |h 163-171 | ||